StreetInsider.com News Articles

Form S-8 Nasus Pharma Ltd

Mon, 19 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261019/27204555.html

Form 6-K Nasus Pharma Ltd For: Oct 08

Thu, 08 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261008/27167338.html

Citizens Reiterates Market Outperform Rating on Nasus Pharma Ltd (NSRX)

Wed, 30 Sep 2026 02:41:03 -0400

Citizens analyst Jason Butler reiterated a Market Outperform rating and $18.00 price target on Nasus Pharma Ltd (NYSE: NSRX)

The analyst comments: “Clinical advancement of NS003 underscores the value of the Nasax platform; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target on Nasus Pharma. This morning, Nasus announced enrollment and dosing of the first patient in the Phase 1 trial evaluating NS003, intranasal ondansetron, in line with timing expectations. The company aims to report top-line PK results by YE 2026. In our view, continued pipeline expansion highlights the value of the Nasax platform.

NS003 is an intranasal powder

Nasus Pharma doses first patient in Phase 1 NS003 nasal study

Tue, 29 Sep 2026 08:00:19 -0400

Nasus Pharma Ltd. (NYSE: NSRX) announced that the first patient has been enrolled and dosed in a Phase 1 pharmacokinetic trial of NS003, its intranasal powder formulation of ondansetron, according to a company press release. The drug is being developed to treat chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting.

The Phase 1 study will assess the pharmacokinetic and safety profile of NS003 in human patients for the first time. In prior pre-clinical animal studies, NS003 showed a pharmacokinetic profile described as comparable to intravenous ondansetron, with similar time to maximum concentration and area under the curve results. A separate

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Tue, 29 Sep 2026 08:00:00 -0400

TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 pharmacokinetic (PK) trial of NS003, its proprietary intranasal powder formulation of ondansetron being developed for chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV).

In a recent pre-clinical study comparing NS003 to the intravenous (“IV”) formulation of ondansetron in animals, results showed that NS003 had a PK profile

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Tue, 29 Sep 2026 08:00:00 -0400

In a recent pre-clinical study comparing NS003 to the intravenous (“IV”) formulation of ondansetron in animals, results showed that NS003 had a PK profile

Form 3 Nasus Pharma Ltd For: Sep 19 Filed by: Elmaliah Oren

Wed, 23 Sep 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260923/27092998.html

Form 4 Nasus Pharma Ltd For: Sep 18 Filed by: Rubin Eyal

Mon, 21 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260921/27085372.html

Form 424B5 Nasus Pharma Ltd

Fri, 18 Sep 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260918/27081063.html

Form 6-K Nasus Pharma Ltd For: Sep 18

Fri, 18 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260918/27080569.html

Form 6-K Nasus Pharma Ltd For: Sep 14

Mon, 14 Sep 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260914/27055798.html

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Mon, 14 Sep 2026 08:00:00 -0400

Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional

Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027

TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the U.S. Food and Drug Administration (“FDA”) has

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Mon, 14 Sep 2026 08:00:00 -0400

Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027

Form EFFECT Nasus Pharma Ltd

Mon, 14 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260914/27054895.html

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:30:00 -0400

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.

The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:30:00 -0400

The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal

Form 6-K Nasus Pharma Ltd For: Sep 04

Fri, 04 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260904/27029906.html

Form F-3 Nasus Pharma Ltd

Tue, 01 Sep 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260901/27013577.html

Form EFFECT Nasus Pharma Ltd

Fri, 21 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26958186.html

Form EFFECT Nasus Pharma Ltd

Fri, 21 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26958186.html

Form 6-K Nasus Pharma Ltd For: Aug 19

Wed, 19 Aug 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260819/26948138.html

Form 6-K Nasus Pharma Ltd For: Aug 19

Wed, 19 Aug 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260819/26948138.html

Nasus Pharma CFO departs, interim replacement named

Wed, 19 Aug 2026 07:00:23 -0400

Nasus Pharma Ltd. (NYSE American: NSRX) announced that Chief Financial Officer Eyal Rubin is leaving the company to pursue an opportunity outside the life sciences industry. Rubin's last day is set for September 18, 2026.

Oren Elmaliach, the company's Director of Finance, has been appointed Interim Chief Financial Officer. Elmaliach has been with Nasus Pharma since its founding and holds a certified public accountant designation with more than 15 years of financial experience, including work with public and private life sciences companies and within U.S. public markets and financial reporting.

"While I am disappointed that Eyal will be leaving Nasus, I am

Nasus Pharma CFO departs, interim replacement named

Wed, 19 Aug 2026 07:00:23 -0400

"While I am disappointed that Eyal will be leaving Nasus, I am

Nasus Pharma Announces Transition of Chief Financial Officer

Wed, 19 Aug 2026 07:00:00 -0400

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer.